Atara Biotherapeutics to Submit New FDA Biologics License Application in 2Q
By Sabela Ojea
Atara Biotherapeutics said it plans to submit a biologics license application for tabelecleucel following productive conversations with the U.S. Food and Drug Administration.
The biopharmaceutical company and the FDA are now aligned and it expects to submit the application in the second quarter of 2024, Atara Biotherapeutics said Tuesday.
The BLA submission for tabelecleucel "will enable Atara to incorporate the latest tab-cel pivotal trial data from the Allele study into the BLA filing package," it said.
Tabelecleucel, approved in the European Union, is being developed for relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a rare hematologic cancer.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 19, 2023 16:35 ET (20:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk